ANALYSIS OF THE EFFECTIVENESS OF SOTROVIMAB IN PATIENTS DIAGNOSED WITH COVID-19

BACKGROUND AND IMPORTANCE
- Sotrovimab is indicated in treatment of COVID19 in adults and adolescents who do not require supplemental oxygen and who are at increased risk of progressing to COVID-severe.
- The drug is administered according to prioritization criteria published by the Spanish Agency of Medicines and Health Products (AEMPS).

AIM AND OBJECTIVES
To analyze the effectiveness of sotrovimab and to know the profile of patients

MATERIAL AND METHODS
Observational, retrospective and descriptive study in a tertiary level hospital. Patients who had received sotrovimab from January/2022-May/2022. Effectiveness was measured as rate of patients without progression to COVID-severe (defined as hospitalization/death at 29 days).

RESULTS
- 37 patients were included, mean age 61 years (21-82), 20 women (54.05%).
- 29 (78.38%) had mild-moderate COVID.
- According to the AEMPS prioritization criteria, all belonged to the group of "Immunocompromised persons and high-risk conditions, regardless of vaccination status".
- 7 patients (18.9%) were hospitalized/dead at 29 days (3 exitus). All these patients had received rituximab.
- 30 patients (81.1%) did not progress to severe COVID.
- 6 patients attended the emergency department, without admission.

CONCLUSION AND RELEVANCE
Most patients presented good response and tolerance to treatment. This result was independent of previous treatments or risk factors. Previous treatment with anti-CD20 seems to show a tendency to progression to severe COVID. Long-term studies are needed to confirm results.